WuXi AppTec has reached a definitive agreement to sell its China-based clinical research services subsidiaries, WuXi Clinical and WuXi MedKey, to Hillhouse Investment Management, a global private asset manager. The deal is part of WuXi AppTec’s strategic effort to sharpen its focus on its Contract Research, Development, and Manufacturing Organization (CRDMO) platform, a move aimed at enhancing the company's core strengths in drug discovery, laboratory testing, process development, and manufacturing services.
WuXi Clinical and MedKey represent major portions of WuXi AppTec’s clinical research and site management operations in China. According to the company, this divestiture enables greater financial flexibility and supports the company’s vision of boosting its global CRDMO capabilities to better serve pharmaceutical clients worldwide. Financial terms of the transaction were not disclosed, but WuXi noted that both divested units together generated approximately 1.16 billion yuan in unaudited revenue for the first nine months of 2025, comprising about 3.5% of WuXi AppTec’s total revenue in that period.
This latest step follows similar divestitures earlier in the year, including WuXi’s U.S. medical device testing business and cell therapy operations, both sold to U.S. investors. Executives commented that these moves will accelerate investment in core CRDMO services amidst an evolving global regulatory landscape and rising demand for end-to-end drug development solutions, positioning WuXi AppTec as a focused global leader in advanced pharmaceutical service provision.